VA
SYRE icon

VR Adviser’s Spyre Therapeutics SYRE Stock Holding History

VR Adviser’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265M Sell
2,985,448
-700,000
-19% -$51.1M 8.04% 4
2026
Q1 		$186M Hold
3,685,448
– – 6.94% 4
2025
Q4 		$121M Buy
3,685,448
+1,000,000
+37% +$26.1M 5.96% 4
2025
Q3 		$45M Hold
2,685,448
– – 2.53% 14
2025
Q2 		$40.2M Hold
2,685,448
– – 3.01% 9
2025
Q1 		$43.3M Hold
2,685,448
– – 3.69% 8
2024
Q4 		$62.5M Hold
2,685,448
– – 4.29% 7
2024
Q3 		$79M Hold
2,685,448
– – 4.14% 6
2024
Q2 		$63.1M Buy
2,685,448
+513,666
+24% +$17.3M 4.02% 9
2024
Q1 		$82.4M Sell
2,171,782
-200,932
-8% -$5.82M 3.92% 4
2023
Q4 		$51.1M Buy
2,372,714
+2,077,680
+704% +$28.6M 3.5% 8
2023
Q3 		$3.61M Buy
295,034
+41,305
+16% +$546K 0.38% 33
2023
Q2 		$2.86M Buy
+253,729
New +$1.2M 0.46% 26

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VR Adviser's SYRE Position: Q2 2026 in Review

VR Adviser reduced its Spyre Therapeutics (SYRE) stake by 19% in Q2 2026, selling an estimated $51.1M and leaving 2,985,448 shares worth $265M. The position accounts for 8.04% of the portfolio, ranked #4.

VR Adviser first reported a position in SYRE in Q2 2023 and has held it in 13 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • VR Adviser held 2,985,448 shares of Spyre Therapeutics worth $265M as of Q2 2026.
  • VR Adviser sold 700,000 Spyre Therapeutics shares in Q2 2026, an estimated $51.1M.
  • Spyre Therapeutics made up 8.04% of VR Adviser's portfolio in Q2 2026, its #4 holding.
  • VR Adviser first reported a position in Spyre Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.